Merck's KEYTRUDA franchise continues to expand into new indications while a novel LDL-lowering drug nears FDA decision — updating our thesis on the $300 billion pharma giant trading at 16.7x earnings.
Two material developments have shifted the Merck thesis since our previous analysis in "Merck's KEYTRUDA Expansion and the FDA Pipeline Decision." First, KEYTRUDA has received expanded indications that broaden its addressable patient population — the drug's total addressable market continues to grow even as the 2028 patent cliff looms. Second, Merck's novel LDL-lowering drug is now approaching an FDA decision, representing a potential new revenue pillar that the market hasn't fully valued.
The stock trades at $121.49 with a market cap of $300 billion, a trailing P/E of 16.7x, and a forward P/E of 23.8x. That forward multiple expansion tells you the Street expects earnings to compress — the KEYTRUDA cliff is already being priced in. The question is whether the pipeline can offset the cliff, and the latest data points suggest the answer is closer to yes than the multiple implies.
Our earlier analysis flagged the core tension in Merck's story: KEYTRUDA generates roughly 55% of total revenue and faces biosimilar competition starting in 2028. The bull case rested on pipeline diversification and indication expansion buying time for new growth drivers to mature. The bear case was simple — no single drug has ever successfully been replaced by a pipeline of smaller assets without a meaningful earnings gap.
Historically, pharma companies approaching patent cliffs have traded at 10-14x earnings. Merck at 16.7x is getting a premium, which means the market is pricing in at least partial pipeline success. The question is whether that premium is justified or generous.
TickerXray Report
Get the complete Merck report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Merck's new LDL-lowering drug represents the most commercially significant pipeline asset outside of oncology. The cardiovascular market is enormous — statins alone generate over $15 billion in annual global sales — and a novel mechanism of action with a favourable safety profile could carve out meaningful share.
The FDA decision timeline puts a potential approval in the second half of 2026, with a commercial launch in early 2027. If approved, consensus estimates suggest peak sales of $3-5 billion, which would represent roughly 5-8% of current revenue. That's not enough to replace KEYTRUDA, but it's a meaningful offset that reduces the severity of the patent cliff.
The last time a major pharma company successfully launched a cardiovascular blockbuster alongside an oncology franchise was Pfizer with Eliquis in the mid-2010s. The stock re-rated 30% over 18 months as the market recognised the diversification value. Merck could follow a similar pattern if the LDL data holds up.
Full-year 2025 revenue of $65.0 billion represents a 1.2% increase over 2024's $64.2 billion — modest, but consider the base effect. Net income of $18.3 billion gives a profit margin of 28.1%, comfortably above the pharma sector average of 20-22%. The operating margin of 32.8% is a cycle high for Merck.
The balance sheet carries $14.6 billion in cash against $46.8 billion in long-term debt. That leverage ratio looks elevated, but pharma companies routinely carry debt to fund acquisitions and can service it comfortably from operating cash flow. Merck's interest coverage ratio remains healthy at over 8x.
The 2.6% dividend yield provides a floor. Merck has increased its dividend for 12 consecutive years, and the payout ratio of roughly 44% leaves room for continued increases even through the KEYTRUDA transition period.
Our thesis has strengthened since the last look. The KEYTRUDA expansion buys more time than we initially credited, and the LDL drug adds a genuinely new revenue vector that wasn't in the previous model. At 16.7x trailing earnings, Merck is pricing in the patent cliff but undervaluing the pipeline offset.
We'd be accumulating below $120 with a 12-month target of $140-150. The catalyst path is clear: FDA decision on the LDL drug in H2 2026, continued KEYTRUDA indication expansions, and potential bolt-on acquisitions funded by the $12+ billion in annual free cash flow. The risk remains binary around the 2028 cliff, but the probability of a smooth transition has increased materially since our last analysis.
Full forensic analysis of Merck
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
Keytruda is the largest single oncology product in pharma history. It will lose primary patent protection in 2028. Merck's strategy to replace the revenue runs across subcutaneous formulation, label expansion, M&A, and a deep clinical pipeline. The Research Desk walks the full plan.
Keytruda revenue crossed $28 billion in 2025. The patent cliff arrives in 2028. The pipeline detail, the HIV expansion, and the ADC portfolio together suggest the revenue replacement math is already substantially solved.
Keytruda loses US exclusivity in 2028. The pipeline covers half the $15-20 billion revenue hole. The replacement gap is what the multiple is discounting.